NEW YORK--(BUSINESS WIRE)--Paige, a leader in next-generation AI technology, announces the launch of OmniScreen, a pioneering AI-driven biomarker module capable of evaluating over 505 genes and detecting 1,228 molecular biomarkers from routine H&E-stained digital pathology slides. Built on Paige’s second-generation foundation model, trained on an unprecedented three million slides, this breakthrough represents a major leap forward in the accuracy, speed, and cost-effectiveness of cancer diagnosis and treatment selection..

。这一突破建立在Paige的第二代基金会模型的基础上，经过前所未有的300万张幻灯片的训练，代表着癌症诊断和治疗选择的准确性、速度和成本效益的重大飞跃。。

Unlike traditional methods that require separate models for each biomarker or cancer type, Paige OmniScreen employs a single AI module capable of predicting a broad spectrum of clinically relevant molecular biomarkers across multiple cancer types. By replicating a targeted biomarker gene panel of 505 genes, it can simultaneously predict 1,228 biomarkers in the 15 most common cancers, including actionable targets such as BRAF, EGFR, KRAS, MET and FGFR3.

与需要为每种生物标志物或癌症类型建立单独模型的传统方法不同，Paige OmniScreen使用了一个AI模块，能够预测多种癌症类型中广泛的临床相关分子生物标志物。通过复制505个基因的靶向生物标志物基因组，它可以同时预测15种最常见癌症中的1228种生物标志物，包括BRAF，EGFR，KRAS，MET和FGFR3等可行靶标。

Additionally, it links phenotypes with genetic patterns, simplifying the diagnosis of conditions defined by specific genetic markers. This capability unlocks deeper, more comprehensive insights into cancer biology and paves the way for new treatment strategies..

此外，它将表型与遗传模式联系起来，简化了对特定遗传标记定义的疾病的诊断。这种能力为癌症生物学提供了更深入，更全面的见解，并为新的治疗策略铺平了道路。。

This technology accelerates drug development by identifying new potential indications through pan-tumor screening for targeted genetic mutations and enhances patient selection for clinical trials. By pre-screening patients before costly molecular tests, Paige OmniScreen offers substantial cost savings for clinical trials and laboratories, ultimately making personalized therapies more accessible and affordable for a broader range of patients..

这项技术通过对靶向基因突变进行泛肿瘤筛查来确定新的潜在适应症，从而加速了药物开发，并增强了患者对临床试验的选择。通过在昂贵的分子检测之前对患者进行预筛查，Paige OmniScreen为临床试验和实验室节省了大量成本，最终使更广泛的患者更容易获得和负担得起个性化治疗。。

“The development of our digital biomarker panel represents a significant advancement in personalized medicine, addressing many of the challenges associated with traditional molecular biomarker tests,” said Razik Yousfi, CTO and CEO of Paige. “Our innovative approach minimizes the need for extensive tissue samples, making it particularly useful in cases where biopsy tissue is limited.

Paige首席技术官兼首席执行官拉齐克·优素菲（Razik Yousfi）表示：“我们的数字生物标志物小组的开发代表了个性化医学的重大进步，解决了与传统分子生物标志物测试相关的许多挑战。”。“我们的创新方法最大程度地减少了对大量组织样本的需求，使其在活检组织有限的情况下特别有用。

This first of its kind AI-module offers detailed insights into cancer biology and potential treatment avenues by predicting the activity of canonical signaling pathways, DNA repair mechanisms, and genomic instability measures.”.

这是第一个此类AI模块，通过预测经典信号通路的活性，DNA修复机制和基因组不稳定性测量，提供了对癌症生物学和潜在治疗途径的详细见解。”。

“Such comprehensive analysis is crucial in identifying genetic alterations and holds immense potential for guiding therapy selection, improving treatment efficacy, and accelerating patient screening for clinical trials,” stated Dr. David Klimstra, Founding Medical Officer of Paige. “By enabling the quick identification of cases that warrant further genomic testing, we’re enhancing clinical decision-making, reducing turnaround times, and lowering testing costs—all while ensuring the highest standards of patient care.

。“通过快速识别需要进一步基因组检测的病例，我们正在加强临床决策，减少周转时间，降低检测成本，同时确保最高标准的患者护理。

This is a game-changer in the pursuit of better cancer treatments and improved patient outcomes.”.

在追求更好的癌症治疗和改善患者预后方面，这是一个游戏规则的改变者。”。

Paige's new OmniScreen module is a testament to the company's unwavering commitment to revolutionizing cancer diagnostics and treatment. By overcoming the limitations of traditional biomarker testing, this system represents a pivotal advancement in the pursuit of precision medicine, ensuring that patients receive the most effective, tailored care possible..

Paige的新OmniScreen模块证明了该公司坚定不移地致力于彻底改变癌症诊断和治疗。通过克服传统生物标志物测试的局限性，该系统代表了追求精准医学的关键进步，确保患者尽可能获得最有效，量身定制的护理。。

About Paige

关于Paige

Paige is pushing the boundaries of AI to solve cancer’s most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data from Memorial Sloan Kettering Cancer Center, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions.

Paige正在推动人工智能的边界，以解决癌症最关键的问题，用下一代技术彻底改变癌症护理。通过独家访问纪念斯隆·凯特琳癌症中心（Memorial Sloan Kettering Cancer Center）提供的数百万张数字化病理幻灯片、临床报告和基因组数据，佩奇对癌症有了全面的了解，涵盖了性别、种族、种族和地理区域等多种因素。

This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-approved AI application in pathology.

这些全面的数据使Paige能够创建先进的AI解决方案，重新定义癌症检测，诊断和治疗。凭借对组织的独特而复杂的理解，Paige在精确诊断方面建立了新的标准，成为FDA批准的第一个AI在病理学中的应用。

Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit www.paige.ai..

Paige还为癌症开发了第一个百万幻灯片基金会模型，继续在发现新见解并将其转化为改变生活的产品方面发挥领导作用。有关更多信息，请访问www.paige.ai。。